St. Modwen Properties PLC Appoints Sarah Whitney as Non-Exec Director

St. Modwen Properties

St. Modwen Properties PLC, (LON: SMP) an expert developer and regeneration specialist, today announced that Sarah Whitney will be appointed as a non-executive director with immediate effect. Sarah will join the Audit, Nomination and Remuneration Committees of the Board on her appointment.

Sarah, a Chartered Accountant, has more than 30 years’ experience in the real estate and corporate finance sectors, including a particular focus on public private partnerships. She currently holds several senior appointments including acting as a member of the Supervisory Board of FTSE250-listed global infrastructure investment company, BBGI SICAV SA; trustee and chair of the audit committee at The Land Restoration Trust; and trustee and chair of the investment committee at The Canal & River Trust. She is Treasurer and a member of the Council of University College London, where she also chairs the Investment Committee, and a Senior Visiting Fellow at the University of Cambridge Department of Land Economy.

Sarah’s prior roles include five years as an Executive Director at CBRE until 2012, three years as a Managing Director at DTZ Holdings, and seven years at PricewaterhouseCoopers (five years as partner) specialising in corporate finance.

Danuta Gray, Chairman of St. Modwen, said:

“I am delighted Sarah is joining the Board. She has extensive experience of real estate across the entire life cycle of the industry as well as a strong financial background and experience of governance matters. This, combined with her particular experience helping to forge strong public private partnerships, will add to our collective expertise and strengthen our Board.”

There is no further information that is required to be disclosed under paragraph 9.6.13R of the Listing Rules of the Financial Conduct Authority.

Share on:

Latest Company News

Ur-Energy advances Lost Soldier uranium project

Ur-Energy has commenced baseline fieldwork at its Lost Soldier uranium project in Wyoming and expects to publish a technical...

Rhythm Pharmaceuticals reports sustained BMI reductions in two-year obesity trial

Rhythm Pharmaceuticals has reported sustained BMI reductions after two years of setmelanotide treatment in patients with acquired hypothalamic obesity....

Verici Dx provides PTRA testing for phase 2 organ transplant clinical trial

Verici Dx has secured an order from Asahi Kasei Therapeutics to provide blood-based biomarker testing, including its PTRA assay,...

Elemental reports record revenue and expands royalty portfolio following Orion acquisition

Elemental Royalty Corporation reported record year-to-date revenue of almost US$70m and approximately 15,100 gold equivalent ounces for the first...

Telecom operators risk failed transformations without clear business plans

Telecom operators risk wasting millions on technology upgrades without clear business objectives. Successful transformation requires simpler processes, executive accountability...

Worldwide Healthcare Trust H1 2026 results impress with 14.8% total return (LON: WWH)

Worldwide Healthcare Trust has reported a 9.3% NAV total return and a 14.8% share price total return for the...

    Search